Skip to main content

Table 1 Demographics and baseline characteristics

From: Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study

Characteristic

Eligible patients

(N = 727)

Sex, n (%), male

478 (65.8)

Age, mean (SD), years (n = 725)

67.2 (8.8)

BMI, mean (SD), kg/m2 (n = 720)

26.4 (5.2)

Current smoker, n (%)

202 (27.8)

Smoking history, mean (SD), pack-years (n = 723)

43.1 (24.8)

Post-bronchodilator FEV1, mean (SD), L (n = 696)

1.4 (0.6)

% predicted FEV1, mean (SD) (n = 718)

52.8 (20.5)

COPD severity, n (%)

 

GOLD group I (mild)

63 (8.7)

GOLD group II (moderate)

265 (36.5)

GOLD group III (severe)

261 (35.9)

GOLD group IV (very severe)

73 (10.0)

mMRC grade, mean (SD)

1.8 (1.0)

mMRC dyspnoea grade, n (%)

 

0

53 (7.3)

1

244 (33.6)

2

244 (33.6)

3

140 (19.3)

4

44 (6.1)

Patients with an exacerbation in previous year, n (%)

392 (53.9)

Number of COPD exacerbations in previous year, mean (SD) (n = 724)

1.2 (1.6)

Current COPD medication, n (%)a

 

LABAs + LAMAs + ICS

355 (48.8)

LABAs + ICS

100 (13.8)

LABAs + LAMAs

70 (9.6)

LABAs alone

66 (9.1)

LAMAs alone

50 (6.9)

Short-acting bronchodilatorsb

22 (3.0)

LABAs + LAMAs + ICS + PDE4 inhibitor

15 (2.1)

LAMAs + ICS

8 (1.1)

Otherc

19 (2.6)

No treatment

22 (3.0)

Total CAT score, mean (SD) (n = 721)

16.5 (8.1)

CAT score category, n (%)

 

CAT score ≤10, n (%)

187 (25.7)

CAT score 11–20, n (%)

305 (42.0)

CAT score 21–30, n (%)

187 (25.7)

CAT score >30, n (%)

42 (5.8)

HADS anxiety score, mean (SD) (n = 710)

6.1 (4.2)

HADS depression score, mean (SD) (n = 714)

5.5 (4.1)

CASIS score, mean (SD) (n = 712)

44.1 (19.1)

  1. n = patients with available data for each outcome; percentages are based on N = 727 patients.
  2. aUsed by >1% of patients.
  3. bIncludes: SABA alone; SABA + SAMA; SAMA alone.
  4. cIncludes: ICS alone; ICS + PDE4 inhibitor; LABA + ICS + PDE4 inhibitor; LAMA + LABA + PDE4 inhibitor.
  5. BMI, body mass index; CASIS, COPD and Asthma Sleep Impact Scale; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Scale; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; PDE4, phosphodiesterase 4; SABA, short-acting β2 agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation.